Yüksel Ürün

3.5k total citations · 1 hit paper
136 papers, 1.1k citations indexed

About

Yüksel Ürün is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Yüksel Ürün has authored 136 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Oncology, 65 papers in Pulmonary and Respiratory Medicine and 31 papers in Surgery. Recurrent topics in Yüksel Ürün's work include Cancer Immunotherapy and Biomarkers (32 papers), Renal cell carcinoma treatment (27 papers) and Prostate Cancer Treatment and Research (23 papers). Yüksel Ürün is often cited by papers focused on Cancer Immunotherapy and Biomarkers (32 papers), Renal cell carcinoma treatment (27 papers) and Prostate Cancer Treatment and Research (23 papers). Yüksel Ürün collaborates with scholars based in Türkiye, United States and United Kingdom. Yüksel Ürün's co-authors include Emre Yekedüz, Güngör Utkan, Toni K. Choueiri, Jeffrey J. Leow, Joaquim Bellmunt, Erin M. Anderson, Andrew Rothman, Chirayu G. Patel, Steven L. Chang and Richard J. Côté and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Yüksel Ürün

108 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials

2013 277 citations Yüksel Ürün, Toni K. Choueiri et al. European Urology profile →

Peers

Yüksel Ürün

ONCOL

SURGE

PRM

Emil Scosyrev United States

Jyoti Bajpai India

Rafael Morales‐Barrera Spain

Antonio Benito Porcaro Italy

Chuang‐Chi Liaw Taiwan

Robert F. Tarrell United States

Cun Liao China

Sunjay Jain United Kingdom

Sunil Kumar India

Evi Comploj Italy

Emil Scosyrev United States

Yüksel Ürün

280 ×0.6

ONCOL

781 ×1.9

SURGE

704 ×2.1

PRM

345 ×2.2

111 ×0.9

Citations per year, relative to Yüksel Ürün Yüksel Ürün (= 1×) peers Emil Scosyrev

Countries citing papers authored by Yüksel Ürün

Since Specialization

Citations

This map shows the geographic impact of Yüksel Ürün's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yüksel Ürün with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yüksel Ürün more than expected).

Fields of papers citing papers by Yüksel Ürün

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yüksel Ürün. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yüksel Ürün. The network helps show where Yüksel Ürün may publish in the future.

Co-authorship network of co-authors of Yüksel Ürün

This figure shows the co-authorship network connecting the top 25 collaborators of Yüksel Ürün. A scholar is included among the top collaborators of Yüksel Ürün based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yüksel Ürün. Yüksel Ürün is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kuzu, Omer F., Sung Hoon Sim, Deniz Tural, et al.. (2025). Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC). Clinical & Translational Oncology. 27(7). 3110–3120.

Kuzu, Omer F., Sung Hoon Sim, Deniz Tural, et al.. (2025). Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma. BMC Cancer. 25(1). 1220–1220.

Azad, Arun, Andrew J. Armstrong, Eva Hellmis, et al.. (2025). Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with androgen receptor pathway inhibitors in patients with metastatic hormone-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01).. Journal of Clinical Oncology. 43(5_suppl). 1 indexed citations

Galsky, Matthew D., Michiel S. van der Heijden, Thomas Powles, et al.. (2025). Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial. European Urology. 88(4). 325–330.

Yekedüz, Emre, et al.. (2025). Impact of comorbidity on survival in cancer patients receiving immune checkpoint inhibitors. Clinical & Translational Oncology. 27(7). 3175–3182. 2 indexed citations

Ürün, Yüksel, et al.. (2025). Assessing the accuracy of the GPT-4 model in multidisciplinary tumor board decision prediction. Clinical & Translational Oncology. 27(9). 3793–3802. 5 indexed citations

Akkuş, Erman, Çağatay Arslan, & Yüksel Ürün. (2024). Advancements in platinum chemotherapy for metastatic castration-resistant prostate cancer: Insights and perspectives. Cancer Treatment Reviews. 130. 102818–102818. 6 indexed citations

Yekedüz, Emre, David A. Braun, Chris Labaki, et al.. (2024). 24 Applying genomic analysis to refine unclassified renal cell carcinoma. The Oncologist. 29(Supplement_1). S20–S20. 1 indexed citations

Ürün, Yüksel, et al.. (2024). Emerging Strategies in Adjuvant Immunotherapy: A Comparative Review of Bladder Cancer and Renal Cell Carcinoma Treatments. Clinical Medicine Insights Oncology. 18. 1383378198–1383378198. 1 indexed citations

10.

Galsky, Matt D., Guru Sonpavde, Thomas Powles, et al.. (2024). Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial.. Journal of Clinical Oncology. 42(16_suppl). 4509–4509. 11 indexed citations

11.

Arslan, Çağatay, Mert Başaran, İrfan Çiçin, et al.. (2024). Perceptions and Expectations: A Study on Prognostic Perception and Quality of Life in Patients With Metastatic Renal and Bladder Cancer. JCO Global Oncology. 10(10). e2400201–e2400201. 1 indexed citations

12.

Yekedüz, Emre, et al.. (2024). Meta-analysis of platinum chemotherapy combinations with immunotherapy in metastatic urothelial carcinoma. The Oncologist. 29(11). 999–1002.

13.

Ürün, Yüksel. (2024). Fumarate hydratase–deficient renal cell carcinoma.

14.

Ürün, Yüksel, et al.. (2023). Adjuvant therapy for renal cell carcinoma: A systematic review of current landscape and future directions. Critical Reviews in Oncology/Hematology. 192. 104144–104144. 2 indexed citations

15.

Ürün, Yüksel, et al.. (2023). Nivolumab-induced immune-related neutropenia in a renal cell carcinoma patient. Journal of Oncology Pharmacy Practice. 29(7). 1797–1801.

16.

Ürün, Yüksel, et al.. (2023). Cancer‐associated thrombosis and drug–drug interactions of antithrombotic and antineoplastic agents. Cancer. 129(20). 3216–3229. 10 indexed citations

17.

Yekedüz, Emre, et al.. (2021). mRNA-based COVID-19 Vaccines Appear to not Increase Immune Events in Cancer Patients Receiving Immune Checkpoint Inhibitors. Future Virology. 16(9). 583–585. 2 indexed citations

18.

Güven, Deniz Can, Ramazan Acar, Emre Yekedüz, et al.. (2021). The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study. Current Problems in Cancer. 45(6). 100760–100760. 16 indexed citations

19.

Ürün, Yüksel, et al.. (2020). Prevalence, etiology and risk factors of anemia in patients with newly diagnosed cancer. Supportive Care in Cancer. 28(11). 5235–5242. 21 indexed citations

20.

Alkan, Ali, Filiz Çay Şenler, Tuğba Yavuzşen, et al.. (2016). Breast cancer survivors suffer from persistent postmastectomy pain syndrome and posttraumatic stress disorder (ORTHUS study): a study of the palliative care working committee of the Turkish Oncology Group (TOG). Supportive Care in Cancer. 24(9). 3747–3755. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact